WOLVES HAND (194A) FY2026 Q2 Earnings Report

Quick View

Executive Summary

FY2025 Q2 results: Revenue 28.0B yen (YoY +11.4%), Operating Income 4.4B yen (YoY +41.3%), Ordinary Income 4.5B yen (YoY +45.2%), Net Income 3.0B yen (YoY +69.0%). The company demonstrated robust profit expansion with operating income growth significantly outpacing revenue growth, indicating strong operating leverage. Net profit margin reached 10.7%, improving from the prior period as operating efficiency gains contributed to bottom-line acceleration. Operating cash flow of 4.5B yen remained healthy at 1.51 times net income, confirming cash-backed earnings quality. However, free cash flow turned negative at -0.4B yen due to substantial investing activities totaling -4.9B yen, primarily driven by subsidiary acquisition of -3.7B yen and capital expenditures of -1.2B yen. The company continues to operate as a single segment (veterinary hospital business) with concentrated business exposure.

Performance Drivers

Revenue increased 11.4% YoY to 28.0B yen, driven by organic growth in the veterinary hospital business and contributions from newly consolidated subsidiaries during the period. Cost of sales rose 9.9% to 20.5B yen, resulting in gross profit of 7.5B yen with gross margin improving to 26.9% from 26.4% YoY, reflecting enhanced operational efficiency. SG&A expenses were well-controlled at 3.1B yen (11.0% of revenue), declining as a percentage of sales from 12.1% in the prior period, demonstrating effective cost management and operating leverage benefits. Operating income surged 41.3% to 4.4B yen with operating margin expanding to 15.8% from 12.3% YoY, a notable 3.5 percentage point improvement.

Non-operating income and expenses netted to a small positive contribution of approximately 0.1B yen, comprising minimal interest income of 0.01B yen offset by interest expense of 0.13B yen and other minor items. Ordinary income reached 4.5B yen, advancing 45.2% YoY in line with operating performance.

Extraordinary items added 0.2B yen to pre-tax profit, including gains on asset sales of 0.08B yen, representing a non-recurring factor that boosted net income. Income tax expense of 1.7B yen resulted in an effective tax rate of approximately 36.6%. Net income of 3.0B yen grew 69.0% YoY, with the acceleration beyond operating income growth partly attributable to the extraordinary gains and tax effects.

The earnings pattern is characterized as revenue up/profit up with profit growth substantially exceeding revenue growth, driven by margin expansion through operating efficiency gains and supplemented by non-recurring gains.

Segment Analysis

The company operates a single business segment in veterinary hospital operations. Segment information disclosure is omitted due to immateriality of other segments. The veterinary hospital business represents 100% of consolidated revenue and operating income, constituting the core business with full concentration of operational and financial exposure in this sector.

Key Metrics

[Profitability] ROE of 9.8% represents solid return on equity, supported by net profit margin of 10.7% and operating margin of 15.8%, both showing year-over-year improvement. The operating margin expansion of 3.5 percentage points reflects strong operational leverage as SG&A ratio declined despite revenue growth. Gross margin of 26.9% improved modestly from 26.4% YoY. [Cash Quality] Cash and deposits stood at 6.5B yen, declining from 8.9B yen YoY, with the reduction attributable to substantial investing activities. Operating cash flow of 4.5B yen exceeded net income by 1.51 times, confirming high-quality cash-backed earnings. Cash coverage of current liabilities at 0.49x warrants attention given liquidity positioning. [Investment Efficiency] Asset turnover of 0.448x reflects capital-intensive operations with significant intangible assets. [Financial Health] Equity ratio of 48.9% indicates moderate financial stability. Current ratio of 98.7% falls below the 100% threshold, signaling tight short-term liquidity requiring monitoring. Debt-to-equity ratio approximates 1.05x with interest-bearing debt of 18.5B yen, while interest coverage ratio remains robust at 34.03x demonstrating sufficient debt servicing capacity.

Cash Flow Analysis

Operating cash flow of 4.5B yen represents 1.51 times net income, confirming strong cash generation quality with operating cash flow subtotal before working capital at 6.7B yen. Working capital movements were modest with inventory increase of 0.1B yen, receivables increase of 0.1B yen, and payables increase of 0.3B yen, resulting in minimal working capital impact. Income taxes paid of 2.0B yen represented a significant cash outflow. Investing cash flow of -4.9B yen was driven primarily by subsidiary acquisition of -3.7B yen and capital expenditures of -1.2B yen, with the CapEx-to-depreciation ratio of 1.28x indicating growth investments. Financing cash flow of -2.0B yen reflected debt servicing and capital structure adjustments. Free cash flow of -0.4B yen turned negative due to substantial acquisition activity, though this reflects strategic growth investments rather than operational weakness. Cash and deposits decreased 2.4B yen from 8.9B yen to 6.5B yen, with the decline driven by the large-scale subsidiary acquisition and capital investments while operating activities generated positive cash. Interest paid remained modest at 0.1B yen despite debt levels, consistent with the strong interest coverage ratio.

Earnings Quality

Ordinary income of 4.5B yen versus operating income of 4.4B yen shows minimal non-operating net contribution of approximately 0.1B yen, representing less than 1% of revenue and indicating earnings are primarily driven by core operations. Non-operating items comprised interest income of 0.01B yen and interest expense of 0.13B yen with other minor items netting to a small positive contribution. Extraordinary income of 0.2B yen included gains on asset sales of 0.08B yen, which should be viewed as non-recurring factors contributing approximately 6.7% of pre-tax profit. The gap between ordinary income and net income is primarily explained by the 36.6% effective tax rate rather than extraordinary items. Operating cash flow of 4.5B yen exceeds net income of 3.0B yen, yielding a cash conversion ratio of 1.51x, well above 1.0 and indicating healthy earnings quality with profits converting to cash. The accruals ratio of -2.4% suggests minimal earnings manipulation risk. Core profitability remains strong with operating activities generating sustainable cash flows, though investors should note that net income benefited modestly from non-recurring asset sale gains.

Guidance Update

Full-year guidance projects revenue of 61.5B yen (YoY +12.6%), operating income of 11.0B yen (YoY +21.0%), and ordinary income of 11.0B yen (YoY +21.1%). Q2 progress rates stand at 45.5% for revenue, 40.2% for operating income, and 40.9% for ordinary income against full-year targets. Revenue progress is slightly below the standard 50% midpoint expectation for H1, while operating income progress trails more notably at 40.2%, suggesting potential for H2 weighting or cautious guidance. The company revised its forecast during this quarter, though specific revision details are not quantified in the available data. Given the strong YoY profit growth demonstrated in Q2 (+41.3% operating income) versus full-year guidance of +21.0%, management appears to have incorporated conservative assumptions for H2 or expects moderating growth momentum. Progress rates indicate the company is broadly on track but will require H2 acceleration to achieve the full-year operating profit target, particularly given typical seasonality or integration effects from newly acquired subsidiaries.

Shareholder Returns

The company maintains a zero dividend policy with Q2 dividend of 0 yen and full-year dividend forecast of 0 yen, unchanged from the prior year. No dividend revision occurred during the quarter. Payout ratio is 0% as the company retains all earnings for internal investment and growth initiatives. No share buyback activities are disclosed. Total shareholder return ratio remains at 0%, reflecting a strategic priority on reinvestment in business expansion, including M&A activity evidenced by the 3.7B yen subsidiary acquisition during the period. This capital allocation approach aligns with the company's growth investment phase, though the absence of shareholder returns may warrant evaluation as profitability and cash generation strengthen. With operating cash flow robust at 4.5B yen but offset by substantial investing activities, the company appears to prioritize growth over near-term distributions, which is typical for expansion-focused enterprises but should be reassessed as free cash flow generation improves.

Risk Factors

Business concentration risk remains elevated as the company operates exclusively in the veterinary hospital single segment, creating vulnerability to sector-specific demand fluctuations, regulatory changes affecting veterinary services, or competitive pressure in the animal healthcare market. Any adverse developments in pet ownership trends, pricing constraints, or regional market dynamics could disproportionately impact consolidated performance without diversification benefits.

Intangible asset and goodwill impairment risk is substantial with goodwill of 18.5B yen (60.7% of equity) and total intangible assets of 19.6B yen comprising 31.4% of total assets. These elevated balances stem from M&A activities and create material downside risk should acquired businesses underperform expectations, requiring periodic impairment testing and potentially resulting in significant non-cash charges that would reduce equity and reported profitability.

Liquidity and working capital risk warrants monitoring with current ratio of 98.7% below the 100% threshold, indicating current liabilities of 13.2B yen slightly exceed current assets of 13.0B yen. While cash of 6.5B yen provides immediate liquidity and operating cash flow generation remains strong, the tight short-term position requires careful management of receivables, payables, and debt maturities. Long-term borrowings increased 37.3% YoY to 17.5B yen, and while interest coverage of 34.03x is healthy, refinancing risk and sensitivity to interest rate increases represent potential pressure points if operating performance softens or credit conditions tighten.

Industry Benchmark (Reference - Proprietary Data)

[Industry Position] (Reference - Proprietary Analysis)

The company demonstrates above-median profitability metrics relative to the IT/Telecom industry peer group. Operating margin of 15.8% exceeds the industry median of 14.0% (IQR: 3.8%-18.5%), positioning the company in the upper half of sector peers for operational efficiency. Net profit margin of 10.7% similarly outperforms the industry median of 9.2% (IQR: 1.1%-14.0%), reflecting effective cost control and profit conversion.

Profitability: ROE 9.8% vs. Industry Median 5.6% (IQR: 0.7%-6.2%); Operating Margin 15.8% vs. Industry Median 14.0% (IQR: 3.8%-18.5%); Net Profit Margin 10.7% vs. Industry Median 9.2% (IQR: 1.1%-14.0%)

Financial Health: Equity Ratio 48.9% vs. Industry Median 60.2% (IQR: 50.8%-88.4%), indicating below-median capitalization with higher financial leverage. Current Ratio 0.99x vs. Industry Median 7.74x (IQR: 3.16x-8.09x), substantially below peers and representing a key area of relative weakness requiring attention.

Efficiency: Asset Turnover 0.448x vs. Industry Median 0.35x (IQR: 0.29-0.37), showing superior asset utilization despite capital-intensive operations. Revenue Growth YoY 11.4% underperforms Industry Median 21.0% (IQR: 15.5%-26.8%), suggesting slower top-line expansion relative to sector peers though profitability per revenue unit is higher.

Financial Leverage 2.05x vs. Industry Median 1.55x (IQR: 1.13-1.76) reflects above-average debt utilization to fund growth investments. Cash Conversion Ratio 1.51x exceeds Industry Median 1.22x (IQR: 0.86-1.75), confirming superior earnings quality. CapEx/D&A Ratio 1.28x substantially exceeds Industry Median 0.34x (IQR: 0.24-1.70), indicating aggressive growth capital investment relative to depreciation and peers.

The company's profile combines strong profitability and cash quality with below-peer liquidity and above-peer leverage, consistent with a growth investment phase prioritizing expansion over conservative balance sheet positioning.

※ Industry: IT/Telecom (7 companies), Comparison: 2025-Q2 period, Source: Proprietary analysis

Key Takeaways from Earnings

Strong profitability expansion with operating leverage demonstrated through 41.3% operating income growth on 11.4% revenue growth, driven by gross margin improvement to 26.9% and SG&A efficiency gains resulting in 15.8% operating margin (up 3.5pt YoY). This margin trajectory indicates scalability benefits are materializing as the business grows, supported by high-quality cash earnings with operating cash flow at 1.51 times net income.

Growth investment phase evidenced by substantial M&A activity with 3.7B yen subsidiary acquisition and elevated CapEx-to-depreciation ratio of 1.28x, resulting in negative free cash flow of -0.4B yen despite positive operating cash flow. The company maintains zero dividend policy, channeling all retained earnings toward expansion, which is appropriate for the current growth stage but will require demonstration of acceptable returns on invested capital as integration progresses. Goodwill and intangibles totaling 38.1B yen (61% of total assets) represent concentrated acquisition-related assets requiring successful operational integration to avoid impairment risk.

Liquidity positioning warrants monitoring with current ratio of 98.7% below the 100% threshold and cash declining 27.2% YoY to 6.5B yen, though this is offset by strong operating cash generation of 4.5B yen. Long-term debt increased 37.3% to 17.5B yen, elevating financial leverage to 2.05x (above industry median of 1.55x), but interest coverage remains robust at 34.03x providing debt servicing cushion. The balance sheet structure reflects aggressive growth financing through debt while maintaining adequate though not abundant liquidity, requiring continued operational performance to sustain.

---

This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.

---

AI Financial Analysis

Executive Summary

FY2026 Q2 earnings were strong, with revenue growth translating into materially faster profit growth and higher margins. Revenue increased 11.4% YoY to ¥2.80bn. Operating income rose 41.3% to ¥443m, outpacing sales by a wide margin. Ordinary income increased 45.2% to ¥453m. Net income rose 69.0% to ¥300m, supported by operating leverage and a net extraordinary gain. Gross profit increased to ¥752m and the gross margin expanded by approximately 310bp YoY to 26.9%. Operating margin expanded by approximately 330bp to 15.8%, exceeding the 15% level generally associated with excellent profitability. Net margin improved by approximately 360bp to 10.7%. SG&A expenses increased 8.6% YoY, slower than revenue growth, evidencing favorable cost discipline and operating leverage. EBITDA was ¥537m and the EBITDA margin was 19.2%. Operating cash flow of ¥452m exceeded net income by 1.51x, indicating sound cash realization of reported earnings. However, free cash flow was negative ¥42m after investing outflows, principally including ¥374m for subsidiary acquisitions and ¥121m of capital expenditure. The group remains acquisition-intensive, with goodwill of ¥1.85bn equal to 60.7% of equity and goodwill amortization of ¥87m under JGAAP. Liquidity is tight, as current assets of ¥1.30bn were marginally below current liabilities of ¥1.32bn. Full-year guidance implies a second-half acceleration, as Q2 cumulative progress is 45.5% for revenue, 40.3% for operating income, and 35.8% for net income versus the standard 50% Q2 progress rate. The revised forecast therefore requires stronger second-half earnings delivery, particularly at the net-income level. The company operates solely in the animal hospital business, making earnings exposure concentrated in that operating model and in the performance of acquired facilities.

Profitability Analysis

Annualized DuPont ROE is 19.7%, comprising a 10.7% net profit margin, 0.896x annualized asset turnover, and 2.05x financial leverage. The strongest contributor to the YoY earnings improvement was margin expansion rather than an indicated change in asset productivity. Gross margin rose to 26.9% from approximately 23.8% in the prior-year period, a gain of about 310bp. Operating margin rose to 15.8% from approximately 12.5%, a gain of about 330bp, as revenue grew 11.4% while SG&A grew only 8.6%. This indicates positive operating leverage in the animal hospital platform. Net margin increased to 10.7% from approximately 7.1%, aided by the higher operating profit base and a ¥20.6m extraordinary-income item, partly offset by a ¥0.3m extraordinary loss. The ¥20.6m net extraordinary gain represented about 6.9% of net income, so a portion of Q2 net-income growth was non-recurring. The tax burden was 0.634, equivalent to a 36.5% effective tax rate, which restrained conversion of pre-tax profit into net income relative to a more normalized tax burden. Interest burden was 1.069 because pre-tax income exceeded EBIT, reflecting net non-operating gains including acquisition-related gain on step acquisitions and asset-sale gains. Interest coverage remains very strong at 34.03x on EBIT and 41.29x on EBITDA. JGAAP goodwill amortization was ¥87m, equal to 16.1% of EBITDA, and is therefore a material drag on reported operating income and net income versus an IFRS peer that does not amortize goodwill. EBITDA before goodwill amortization was ¥624m, implying a pre-goodwill-amortization EBITDA margin of approximately 22.3%.

Growth Assessment

The 11.4% revenue increase and 41.3% operating-income increase indicate that current growth is profitable rather than purely volume-led. Gross-profit growth exceeded revenue growth, indicating improved unit economics or a more favorable service and cost mix. The slower growth in SG&A than revenue supports scalability in the operating structure. Capital expenditure of ¥121m exceeded depreciation and amortization of ¥94m, with a 1.28x CapEx/depreciation ratio, indicating continuing reinvestment rather than underinvestment. Acquisition spending of ¥374m was equal to approximately 13.4% of Q2 cumulative revenue, making M&A a meaningful contributor to expansion and raising the importance of integration execution. Two subsidiaries were newly consolidated during the period, consistent with continued inorganic growth activity. Goodwill increased ¥200m YoY to ¥1.85bn, while total intangible assets increased ¥202m to ¥1.96bn. Full-year revenue guidance is ¥6.15bn, implying 12.6% YoY growth, broadly consistent with the first-half revenue-growth rate. Full-year operating-income guidance is ¥1.10bn, implying 21.0% YoY growth, below the 41.3% Q2 cumulative growth rate. Q2 cumulative revenue progress of 45.5% is 4.5 percentage points below standard Q2 progress, while operating-income progress of 40.3% is 9.7 points below standard. Net-income progress of 35.8% is 14.2 points below standard, requiring a notable second-half step-up to achieve the ¥840m forecast. The forecast has been revised, increasing the relevance of subsequent confirmation that acquired operations, pricing, utilization, and cost control can support the implied second-half recovery.

Financial Health

Liquidity requires close monitoring. The current ratio is 98.7%, below 1.0x, and the quick ratio is 88.8%, indicating that current assets do not fully cover current liabilities. Working capital was negative ¥17m. This creates a limited maturity mismatch risk because current liabilities were ¥1.32bn versus current assets of ¥1.30bn. The risk is moderated by the debt maturity profile: short-term debt represented only 5.4% of interest-bearing debt, and cash covered short-term loans by 6.52x. Cash and deposits declined ¥243m YoY to ¥652m, consistent with the ¥244m period cash outflow. Long-term loans increased ¥475m, or 37.3%, to ¥1.75bn, reflecting greater reliance on long-term financing. Total interest-bearing debt was ¥1.85bn, equivalent to 1.05x equity and 37.7% of capital. D/E is above the conservative 1.0x benchmark but well below the 2.0x level associated with aggressive leverage. Debt/EBITDA was 3.44x, a manageable but elevated level relative to a 2.5x investment-grade benchmark; strong interest coverage materially mitigates immediate servicing risk. Total liabilities represented 51.1% of assets, while owners' equity represented 48.8%. Asset quality is heavily influenced by acquired intangibles: goodwill was 29.7% of assets and total intangible assets were 31.3% of assets. Goodwill/equity of 60.7% exceeds the 50% warning threshold, making equity value meaningfully dependent on retained acquisition value and future earnings of acquired businesses. Asset retirement obligations of ¥98m should be monitored as a long-term facility-related obligation in this physical clinic network.

Notable B/S Changes

Retained earnings: +¥300m (+107.7%) to ¥579m - Q2 net income was retained, strengthening accumulated capital in the absence of dividends. Inventories: +¥45m (+52.4%) to ¥131m - inventory growth materially exceeded revenue growth and should be monitored for alignment with clinic activity and consumable demand. Long-term loans: +¥475m (+37.3%) to ¥1.75bn - indicates increased long-term funding for expansion and acquisitions; debt service remains well covered but leverage requires monitoring. Accounts payable: +¥33m (+35.9%) to ¥124m - provides some working-capital funding, though continued growth should be assessed against purchasing activity and payment terms. Cash and deposits: -¥243m (-27.2%) to ¥652m - reflects acquisition, capital-investment, and net financing outflows and contributes to the tight 98.7% current ratio. Goodwill: +¥200m (+12.1%) to ¥1.85bn - acquired-business value remains substantial at 60.7% of equity, elevating future impairment sensitivity. Intangible assets: +¥202m (+11.5%) to ¥1.96bn - intangible assets equal 31.3% of total assets, reinforcing the asset-base dependence on acquired and non-physical value.

Cash Flow Quality

Cash earnings quality was favorable in Q2. Operating cash flow was ¥452m, exceeding net income of ¥300m by 1.51x and therefore comfortably above the 0.8x quality-warning threshold. The accruals ratio was negative 2.4%, consistent with cash conversion that is stronger than accounting earnings. Cash conversion, measured as OCF/EBITDA, was 0.84x, solid although below the 0.9x excellent benchmark. Operating cash generation was supported by the earnings base rather than a large adverse buildup in receivables; trade receivables increased only ¥11m in the cash-flow reconciliation. Inventory increased ¥14m in the cash-flow reconciliation, while the balance-sheet inventory balance rose 52.4% YoY to ¥131m; this warrants monitoring against clinical demand and consumable purchasing needs. Trade payables increased ¥29m in the cash-flow reconciliation and were 35.9% higher YoY, providing some working-capital funding. Operating cash flow was more than sufficient to fund ¥121m of capital expenditure, leaving approximately ¥332m of pre-acquisition free cash flow. Reported free cash flow was negative ¥42m because broader investing cash outflows reached ¥494m, including ¥374m for subsidiary acquisitions. Thus, the negative reported FCF reflects discretionary growth investment and acquisition activity rather than weak operating cash conversion. Financing cash flow was negative ¥202m, mainly because ¥1.05bn of long-term debt repayments exceeded ¥819m of new long-term borrowing. The combined investing and financing outflows reduced cash by ¥244m during the period. Continued acquisition spending funded partly by debt can pressure cash balances and liquidity if operating cash flow does not grow proportionately.

Dividend Sustainability

Q2 DPS was ¥0 and the full-year forecast also indicates ¥0 DPS. Accordingly, the dividend payout ratio is 0% based on the disclosed dividend plan. Retained earnings increased 107.7% YoY to ¥579m, supported by the period's ¥300m net income and the absence of dividend distributions. The lack of cash dividends preserves internally generated capital for debt service, capital expenditure, and acquisitions. Operating cash flow of ¥452m covered ordinary capital expenditure of ¥121m, but reported free cash flow was negative ¥42m after acquisition-related investing activity. Given the current ratio below 1.0x, declining cash, and a debt/EBITDA ratio of 3.44x, capital retention is financially consistent with the current expansion phase. Future shareholder distributions would depend on maintaining operating cash conversion, moderating acquisition cash needs, and preserving balance-sheet capacity. No total return ratio is calculated because no share repurchase amount is disclosed for the period.

Risk Assessment

Business risks include Animal hospital industry concentration: the group is a single-segment animal hospital operator, so demand, pricing, veterinarian availability, clinic utilization, and local competition directly affect consolidated earnings., M&A and integration risk: ¥374m of subsidiary-acquisition spending, two newly consolidated subsidiaries, and ¥1.85bn of goodwill make successful clinical, personnel, systems, and referral-network integration important., Goodwill impairment risk: goodwill equals 60.7% of equity and 3.45x EBITDA. The goodwill/EBITDA multiple is within the healthy payback benchmark, but the high equity concentration means underperformance at acquired facilities could have a material effect on book value and earnings., Personnel risk: animal hospital operations depend on recruiting and retaining veterinarians, nurses, and specialized staff; wage inflation or shortages could reverse recent operating-margin expansion., Demand and cost risk: pet-owner discretionary spending conditions, medical-supply inflation, and competition from independent and chain clinics could pressure visit volumes, treatment mix, and gross margin..

Financial risks include Low liquidity: the 98.7% current ratio is below 1.0x, the quick ratio is 88.8%, and working capital is negative ¥17m. While cash adequately covers short-term loans, the company has little aggregate current-asset coverage surplus., Leverage risk: interest-bearing debt totals ¥1.85bn, D/E is 1.05x, and debt/EBITDA is 3.44x. Interest coverage is strong, but further debt-funded acquisitions could narrow headroom., Cash depletion risk: cash declined ¥243m YoY to ¥652m after negative investing and financing cash flows. Sustained acquisition outlays without commensurate operating-cash growth would intensify liquidity pressure., Intangible-asset concentration: intangible assets equal 31.3% of total assets, above the 30% warning threshold, increasing sensitivity of asset values and returns to acquisition assumptions., JGAAP goodwill-amortization drag: goodwill amortization of ¥87m equals 16.1% of EBITDA. This is a material recurring charge under JGAAP that depresses reported operating and net profit relative to pre-amortization cash earnings..

Key concerns include The principal near-term risk is balancing acquisition-led growth with liquidity management, given a sub-1.0x current ratio and reduced cash reserves., The principal medium-term risk is preserving the value of a goodwill balance that exceeds 60% of equity through sustained acquired-clinic earnings and effective integration., The full-year forecast requires second-half improvement: Q2 net-income progress of 35.8% is 14.2 percentage points below the standard 50% progress rate., Margin expansion is a major strength, but it should be validated through continued gross-margin resilience and SG&A growth remaining below revenue growth..

Investment Implications

Key takeaways include Revenue grew 11.4% YoY, while operating income grew 41.3%, producing a 15.8% operating margin and approximately 330bp YoY margin expansion., Annualized ROE of 19.7% is high, supported by a 10.7% net margin and 2.05x financial leverage., Operating cash flow exceeded net income by 1.51x, supporting the quality of underlying earnings., Reported free cash flow was negative ¥42m because acquisitions and capital investment exceeded operating cash inflow., Goodwill of ¥1.85bn, equal to 60.7% of equity, is the central balance-sheet sensitivity., Liquidity is tight, with a 98.7% current ratio and negative ¥17m working capital, despite strong interest coverage and a predominantly long-term debt profile., The revised full-year forecast requires stronger second-half profit generation than indicated by Q2 cumulative progress..

Metrics to watch include Second-half progress toward ¥6.15bn revenue, ¥1.10bn operating income, and ¥840m net income guidance, Operating margin and gross margin sustainability following Q2 expansion to 15.8% and 26.9%, respectively, Operating cash flow relative to EBITDA and net income, Cash balance, current ratio, and working-capital movement, Debt/EBITDA, long-term borrowing trends, and interest coverage, Acquisition spending, newly consolidated entities, goodwill growth, and any impairment indicators, Goodwill amortization relative to EBITDA and the resulting difference between reported EBITDA and pre-goodwill-amortization EBITDA, Inventory and trade-payable trends relative to revenue growth.

Regarding relative positioning, The company currently demonstrates above-benchmark profitability, with a 15.8% operating margin, 10.7% net margin, and 19.7% annualized ROE. Cash conversion and interest coverage are also favorable. Relative to a conservatively financed service operator, however, its balance sheet is more acquisition-dependent, with debt/EBITDA of 3.44x, goodwill/equity of 60.7%, intangible assets equal to 31.3% of assets, and sub-1.0x current liquidity. JGAAP goodwill amortization materially understates reported operating profit relative to pre-amortization EBITDA, but it also highlights the importance of sustained acquisition economics.